These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 10854429)
1. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. Gouédard L; Chen YG; Thevenet L; Racine C; Borie S; Lamarre I; Josso N; Massague J; di Clemente N J Biol Chem; 2000 Sep; 275(36):27973-8. PubMed ID: 10854429 [TBL] [Abstract][Full Text] [Related]
2. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113 [TBL] [Abstract][Full Text] [Related]
4. Components of the anti-Müllerian hormone signaling pathway in gonads. di Clemente N; Josso N; Gouédard L; Belville C Mol Cell Endocrinol; 2003 Dec; 211(1-2):9-14. PubMed ID: 14656470 [TBL] [Abstract][Full Text] [Related]
5. AMH signaling: from receptor to target gene. Visser JA Mol Cell Endocrinol; 2003 Dec; 211(1-2):65-73. PubMed ID: 14656478 [TBL] [Abstract][Full Text] [Related]
6. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications. Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474 [TBL] [Abstract][Full Text] [Related]
7. Anti-Müllerian hormone and its receptors. Josso N; di Clemente N; Gouédard L Mol Cell Endocrinol; 2001 Jun; 179(1-2):25-32. PubMed ID: 11420127 [TBL] [Abstract][Full Text] [Related]
8. Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line. Belville C; Jamin SP; Picard JY; Josso N; di Clemente N Oncogene; 2005 Jul; 24(31):4984-92. PubMed ID: 15897891 [TBL] [Abstract][Full Text] [Related]
9. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. Dutertre M; Gouédard L; Xavier F; Long WQ; di Clemente N; Picard JY; Rey R Endocrinology; 2001 Sep; 142(9):4040-6. PubMed ID: 11517183 [TBL] [Abstract][Full Text] [Related]
11. Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duct syndrome contrasts with its dominant negative activity in vitro. Messika-Zeitoun L; Gouédard L; Belville C; Dutertre M; Lins L; Imbeaud S; Hughes IA; Picard JY; Josso N; di Clemente N J Clin Endocrinol Metab; 2001 Sep; 86(9):4390-7. PubMed ID: 11549681 [TBL] [Abstract][Full Text] [Related]
12. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. di Clemente N; Wilson C; Faure E; Boussin L; Carmillo P; Tizard R; Picard JY; Vigier B; Josso N; Cate R Mol Endocrinol; 1994 Aug; 8(8):1006-20. PubMed ID: 7997230 [TBL] [Abstract][Full Text] [Related]
13. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. Moore RK; Otsuka F; Shimasaki S J Biol Chem; 2003 Jan; 278(1):304-10. PubMed ID: 12419820 [TBL] [Abstract][Full Text] [Related]
14. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells. Hoshiya Y; Gupta V; Segev DL; Hoshiya M; Carey JL; Sasur LM; Tran TT; Ha TU; Maheswaran S Mol Cell Endocrinol; 2003 Dec; 211(1-2):43-9. PubMed ID: 14656475 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor. Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125 [TBL] [Abstract][Full Text] [Related]
16. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family. Josso N; Clemente Nd Trends Endocrinol Metab; 2003 Mar; 14(2):91-7. PubMed ID: 12591180 [TBL] [Abstract][Full Text] [Related]
17. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228 [TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset. Chalazonitis A; D'Autréaux F; Guha U; Pham TD; Faure C; Chen JJ; Roman D; Kan L; Rothman TP; Kessler JA; Gershon MD J Neurosci; 2004 Apr; 24(17):4266-82. PubMed ID: 15115823 [TBL] [Abstract][Full Text] [Related]
19. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763 [TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins. Chen D; Zhao M; Mundy GR Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]